These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21345512)

  • 1. Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
    Han SJ; Choi SE; Kang Y; Jung JG; Yi SA; Kim HJ; Lee KW; Kim DJ
    Diabetes Res Clin Pract; 2011 May; 92(2):213-22. PubMed ID: 21345512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
    Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
    Shang Q; Liu MK; Saumoy M; Holst JJ; Salen G; Xu G
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G815-23. PubMed ID: 22281473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
    Reimer RA; Grover GJ; Koetzner L; Gahler RJ; Lyon MR; Wood S
    J Endocrinol; 2014 Mar; 220(3):361-73. PubMed ID: 24389593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats.
    Atkinson LL; McDonald-Dyck C; Benkoczi C; Finegood DT
    Diabetes Obes Metab; 2008 Sep; 10(9):780-90. PubMed ID: 17970758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voluntary running exercise prevents β-cell failure in susceptible islets of the Zucker diabetic fatty rat.
    Delghingaro-Augusto V; Décary S; Peyot ML; Latour MG; Lamontagne J; Paradis-Isler N; Lacharité-Lemieux M; Akakpo H; Birot O; Nolan CJ; Prentki M; Bergeron R
    Am J Physiol Endocrinol Metab; 2012 Jan; 302(2):E254-64. PubMed ID: 22045312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.
    Kim YS; Oh SH; Park KS; No H; Oh BJ; Kim SK; Jung HS; Kim JH; Lee MS; Lee MK; Kim KW
    Pancreas; 2011 Aug; 40(6):855-60. PubMed ID: 21747318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.
    Uhles S; Wang H; Bénardeau A; Prummer M; Brecheisen M; Sewing S; Tobalina L; Bosco D; Wollheim CB; Migliorini C; Sebokova E
    Diabetes Obes Metab; 2011 Apr; 13(4):326-36. PubMed ID: 21205124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Energy restriction prevents the development of type 2 diabetes in Zucker diabetic fatty rats: coordinated patterns of gene expression for energy metabolism in insulin-sensitive tissues and pancreatic islets determined by oligonucleotide microarray analysis.
    Colombo M; Kruhoeffer M; Gregersen S; Agger A; Jeppesen P; Oerntoft T; Hermansen K
    Metabolism; 2006 Jan; 55(1):43-52. PubMed ID: 16324918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.
    Hou J; Zheng D; Fan K; Yu B; Xiao W; Ma J; Jin W; Tan Y; Wu J
    Pharmacology; 2012; 90(3-4):177-82. PubMed ID: 22948814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
    Yasuda N; Inoue T; Nagakura T; Yamazaki K; Kira K; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2004 Aug; 310(2):614-9. PubMed ID: 15039452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.